Phase II open label study to establish the safety and efficacy of intravenous loading dose of ibandronate [ibandronic acid] 6 mg in 3 consecutive days in breast cancer patients with skeletal metastases

Trial Profile

Phase II open label study to establish the safety and efficacy of intravenous loading dose of ibandronate [ibandronic acid] 6 mg in 3 consecutive days in breast cancer patients with skeletal metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2006 Status change
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top